Details

Project TitleModification of Inflammation by POP3, a Novel Inflammasome Inhibitor
Track Code2010-160
Short Description

POP3 protein as a method to modulate inflammation. #therapeutics #anti-inflammatory #infectious disease #autoimmunity

Abstract

Northwestern researchers have identified a new member of the PYD-only protein (POPs) family (POP3) as a specific regulator of ALR inflammasomes, promoting IFN-beta production and reducing IL-1beta and IL-8 production. POP3 has the potential for biologic therapy for the modulation of the IL-1beta inflammatory response as well blocking the excessive production of cytokines in inflammatory and autoimmune disease. POP3 could be employed to specifically block IL-1beta generation found in DNA virus and bacteria-induced inflammasome activation; as well as DNA-driven autoimmune disease. Conversely, neutralization of POP3 could be used to boost immune responses for adjuvent activity or to help clear infections.

 
Tagsautoimmunity, THERAPEUTICS: anti-inflammatory, THERAPEUTICS: infectious disease
 
Posted DateMay 28, 2014 6:09 PM

Inventor(s)

Christian Stehlik

Applications

  • Development of POP3-based inflammasome inhibitors to prevent IL-1beta release 
  • Neutralization of POP3 to boost adjuvent activity or aid in clearing infections 

Advantages

  • Potential to inhibit specific inflammatory responses 
  • If neutralized, could boost immune responsiveness

Publications

IP Status

A patent application has been filed. 

Contact Information

Michael Moore, PhD 
Invention Manager 
(p) (847) 491-4645 

(e) michaelmoore@northwestern.edu